Efficacy and safety of intravenous ceftriaxone at home vs intravenous flucloxacillin in hospital for children with cellulitis (CHOICE): A single-centre, open-label, randomized, controlled, non-inferiority trial
The Lancet Infectious Diseases May 01, 2019
Ibrahim LF, et al. - In the Cellulitis at Home or Inpatient in Children from the Emergency Department (CHOICE) trial, intravenous antibiotic therapy at home was compared with standard treatment in hospital for children (aged 6 months to 18 years) with moderate to severe cellulitis regarding effectiveness and safety. Researchers randomly assigned children aged 6 months to 18 years who presented to the emergency department at The Royal Children's Hospital (Melbourne, VIC, Australia) with uncomplicated moderate to severe cellulitis to receive either intravenous ceftriaxone (50 mg/kg once daily; n=95) at home or intravenous flucloxacillin (50 mg/kg every 6 h; n=95) in hospital. Outcomes revealed non-inferiority of home treatment with intravenous ceftriaxone to treatment in hospital with intravenous flucloxacillin, which supports home or outpatient care as the standard of care for intravenous treatment of uncomplicated cellulitis in children, when feasible.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries